Barr M L, Cohen D J, Benvenisty A I, Hardy M, Reemtsma K, Rose E A, Marboe C C, D'Agati V, Suciu-Foca N, Reed E
Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, New York 10032.
Transplant Proc. 1993 Feb;25(1 Pt 1):262-4.
Study of anti-HLA antibodies in a population of 238 primary renal and 199 primary heart allograft recipients showed significant association between development of anti-HLA antibodies and that of chronic allograft rejection. The 5-year renal allograft survival was 70% in recipients without antibodies and 53% in recipients who developed anti-HLA alloantibodies during the first year following transplantation. Heart allograft survival at 5 years was 91% in patients without and 78% in patients with antibodies during the first 12 months posttransplantation. Development of antibodies is associated with acute rejection episodes and probably with the release of soluble HLA antigens.
对238名原发性肾移植受者和199名原发性心脏移植受者群体中抗HLA抗体的研究表明，抗HLA抗体的产生与慢性移植排斥反应之间存在显著关联。在移植后第一年未产生抗体的肾移植受者中，5年肾移植存活率为70%，而产生抗HLA同种抗体的受者中为53%。在移植后前12个月未产生抗体的心脏移植患者中，5年心脏移植存活率为91%，产生抗体的患者中为78%。抗体的产生与急性排斥反应发作相关，可能还与可溶性HLA抗原的释放有关。
